DOI: https://doi.org/10.22263/2312-4156.2024.6.115
H.I. Yakubenka1, T.K. Savunova2
Ocular surface condition in patients with first-diagnosed primary open-angle glaucoma before treatment
1Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
2Institute for Advanced Training & Retraining of Healthcare Personnel of the Educational Institution “Belarusian State Medical University”, Minsk, Republic of Belarus
Vestnik VGMU. 2024;23(6):115-123.
Abstract.
Objectives. To evaluate the ocular surface condition in patients with primary open-angle glaucoma before the start of instillation antiglaucoma therapy.
Material and Methods. 58 patients (79 eyes) were included in the study. The mean age was 65.8 [63; 71] years. There were 14 (24.13%) males and 44 (75.87%) females. All patients were divided into two groups. The main group included 35 patients (56 eyes) diagnosed with primary open-angle I a-b glaucoma (POAG), who had not previously instilled topical antiglaucoma medications. The control group included 23 patients (23 eyes) without the diagnosis of primary open-angle glaucoma. The patients underwent basic ophthalmologic examinations. Additionally, the condition of the eyelid margin, Schirmer I and II tests, tear film breakup time, bulbar conjunctival folds were evaluated, ocular surface staining with vital dyes was performed, the ocular surface disease index and its protection index were calculated.
Results. Patients in the main group more often complained of dryness and painful sensations during eye drops instillation, the median OSDI questionnaire score was 14.5 [13.19; 19.44] points, which corresponded to mild to moderate xerosis. Dysfunction of meibomian glands was found in 93% of cases, decrease in tear film stability – in 78.6% of cases, tear hyperproduction was noted in 64.3% of cases. In 75% of cases patients of the main group had evaporative form of BSG of mild and moderate severity.
Conclusions. Before starting hypotensive therapy in patients with first-diagnosed glaucoma, it is necessary to perform complex diagnostics of the ocular surface condition for timely detection of disorders and their adequate correction.
Keywords: tear film, ocular surface, dry eye disease, primary open angle glaucoma, antiglaucoma therapy, ocular surface.
References
1. Kapetanakis VV, Chan MPY, Foster PJ, Cook DG, Owen CG, Rudnicka AR. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016 Jan;100(1):86-93. doi: http://dx.doi.org/10.1136/bjophthalmol-2015-307223
2. Egorov EA, Erichev VP, red. The National Glaucoma Guidelines. Moscow, RF: GEOTAR-Media; 2019. 384 р. (In Russ.)
3. Sullivan DA, Rocha EM, Aragona P, Clayton JA, Ding J, Golebiowski B, et al. TFOS DEWS 2 Sex, Gender and Hormones Report. Ocul Surf. 2017 Jul;15(3):284-333. doi: http://dx.doi.org/10.1016/j.jtos.2017.04.001
4. Brzheskiy VV, Somov EE. Corneal conjunctival xerosis (diagnosis, clinic, treatment). 2-e izd, pererab i dop. St. Petersburg, RF: Levsha; 2003. 120 р. (In Russ.)
5. Peng CC, Cerretani C, Braun RJ, Radke CJ. Evaporation-driven instability of the precorneal tear film. Adv Colloid Interface Sci. 2014 Apr:206:250-64. doi: http://dx.doi.org/10.1016/j.cis.2013.06.001
6. Sitnik GV, Lebedeva PA, Chekina AYu, Dravitsa LV, Ilina SN, Korolkova NK. Efficacy of 0.1% cationic emulsion of cyclosporine (Ikervis) in the treatment of chronic ocular surface inflammation in dry eye disease (SACURA study). Oftal'mologiya Vostoch Evropa. 2021;11(3):402-415. (In Russ.). doi: http://dx.doi.org/10.34883/ PI.2024.14.2.016
7. Asiedu K, Abu SL. The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review. J Curr Ophthalmol. 2018 Sep 1;31(1):8-15. doi: http://dx.doi.org/10.1016/j.joco.2018.07.003
8. Baudouin C, Renard J-P, Nordmann J-P, Denis P, Lachkar Y, Sellem E, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2012 Jun. doi: http://dx.doi.org/10.5301/ejo.5000181
9. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010 Jun;29(6):618-621. doi: http://dx.doi.org/10.1097/ICO.0b013e3181c325b2
10. Semak GR, Potapnev MP, Zherko IYu, Marushko AV, Smentina AV, Asaevich VA. Application of plasma enriched with soluble platelet factors in the treatment of ocular surface diseases. Oftal'mologiya Vostoch Evropa. 2021;11(1):59-66. (In Russ.). doi: http://dx.doi.org/10.34883/PI.2021.11.1.006
11. Imshenetskaya TA, Vashkevich GV. Preserving quality of life in patients with terminal glaucoma. Retsept. 2009;(2):173-176. (In Russ.)
12. Özcura F, Aydin S, Helvaci MR. Ocular Surface Disease Index for the Diagnosis of Dry Eye Syndrome. Ocul Immunol Inflamm. 2007 Sep-Oct;15(5):389-393. doi: http://dx.doi.org/10.1080/09273940701486803
13. Prozornaya LP. Dry eye syndrome in chronic blepharoconjunctivitis. V: Sovremennye problemy oftal'mologii: sb nauch st. St. Petersburg, RF; 2007. Р. 255-264. (In Russ.)
14. Maychuk YuF, Mironkova EA. The role of meibomian gland dysfunction in the pathogenesis of dry eye syndrome. Choice of drug therapy. Refrakts Khirurgiya Oftal'mologiya. 2007;7(2):51-55. (In Russ.)
15. Prozornaya LP, Brzheskiy VV. Total meibomian index as a criterion for diagnosing meibomian gland dysfunction. V: Nevskie gorizonty – 2012: materialy nauch konf oftal'mologov. St. Petersburg, RF: Politekhnikaservis; 2012. Т 1. Р. 406-412. (In Russ.)
16. Ousler GW, Hagberg KW, Schindelar M, Welch D, Abelson MB. The ocular protection index. Cornea. 2008 Jun;27(5):509-513. doi: http://dx.doi.org/10.1097/ICO.0b013e31816583f6
17. Brzheskiy VV, Egorova GB, Egorov EA. Dry eye syndrome and ocular surface diseases. Clinic, diagnosis, treatment. Moscow, RF: GEOTAR-Media; 2016. 464 р. (In Russ.)
18. Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The International Workshop on Meibomian Gland Dysfunction: report of the subcommitee on the epidemiology and associated risk factors for MGD. Invest Ophthalmol Vis Sci. 2011 Mar;52(4):1994-2005. doi: http://dx.doi.org/10.1167/iovs.10-6997e
19. Ueta M. Innate immunity of the ocular surface and ocular surface inflammatory disorders. Cornea. 2008 Sep:27 Suppl 1:S31-40. doi: http://dx.doi.org/10.1097/ICO.0b013e31817f2a7f
Submitted 19.09.2024
Accepted 04.12.2024
Information about authors:
H.I. Yakubenka – senior lecturer of the Chair of Ophthalmology, Vitebsk State Order of Peoples’ Friendship Medical University, https://orcid.org/0000-0002-9362-9590,
e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Hanna I. Yakubenka;
T.K. Savunova – andidate of Medical Sciences, associate professor, head of the Chair of Ophthalmology, Institute for Advanced Training & Retraining of Healthcare Personnel of the Educational Institution “Belarusian State Medical University”.
